Corinne Godin

Amiens, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Transcriptional Induction of SERPINE1 and Fibrinolysis Inhibition as Predominant Effects of Glucocorticoids on the Cancer Coagulome.

Transcriptional Induction of SERPINE1 and Fibrinolysis Inhibition as Predominant Effects of Glucocorticoids on the Cancer Coagulome.

Journal: Anticancer research
Published: June 17, 2024

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers.

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers.

Journal: Cancers
Published: January 27, 2023

DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU).

DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU).

Journal: Translational oncology
Published: January 22, 2021

SLC7A11 as a biomarker and therapeutic target in HPV-positive head and neck Squamous Cell Carcinoma.

SLC7A11 as a biomarker and therapeutic target in HPV-positive head and neck Squamous Cell Carcinoma.

Journal: Biochemical and biophysical research communications
Published: September 10, 2020

ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.

ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.

Journal: Bioscience reports
Published: May 10, 2019

Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.

Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.

Journal: Oncology reports
Published: June 29, 2018

Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells.

Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells.

Journal: Oncotarget
Published: June 09, 2017

Targeting the Unfolded Protein Response as a Potential Therapeutic Strategy in Renal Carcinoma Cells Exposed to Cyclosporine A.

Targeting the Unfolded Protein Response as a Potential Therapeutic Strategy in Renal Carcinoma Cells Exposed to Cyclosporine A.

Journal: Anticancer research
Published: January 03, 2017

Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.

Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.

Journal: Molecular cancer
Published: February 19, 2016

Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib.

Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib.

Journal: Cancer letters
Published: September 10, 2015

Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.

Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.

Journal: Anticancer research
Published: March 10, 2015

Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.

Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.

Journal: Anticancer research
Published: November 05, 2014
Showing 1-12 of 19

Last Updated: 09/26/2026